undamentalytics Newsletter
Sign in

Bionano Genomics, Inc. cash flow statement

In fiscal 2025, Bionano Genomics, Inc.'s operations generated −$16.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$16.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−21−20−30−38−72−125−125−69−16−20
Depreciation and amortisation21113101414108
Stock-based pay01121022151054
Capital spending1000000000
Free cash flow−22−20−30−38−72−125−125−69−16−20
Free cash flow after stock pay−22−21−31−40−82−147−140−79−21−24
Shares issued—————2358443116

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BNGO vs MXCTBNGO vs RPIDBNGO vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionano Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionano Genomics, Inc.